HIV/AIDS Prognostics: Serum albumin predicts severity of HIV infection and monitors response to HAART

AIDSWEEKLY Plus; Monday, October 2, 2006
Staff Medical Writers

According to a recently published study from Nigeria, "We sought to examine the utility of serum albumin measurement in staging AIDS and monitoring patients' response to therapy.

"The possible importance of serum albumin measurement in assessing AIDS stage and in monitoring the response to highly active antiretroviral therapy using CD4 cell count and body weight as parameters was examined in 185 consecutive HIV-infected, therapy-naive individuals who were recruited for antiretroviral therapy at the university of Ilorin Teaching Hospital."

"The regimen included lamivudine, stavudine and nevirapine. The diagnosis of AIDS was established through a combination of clinical features and HIV seropositivity using two different enzyme-linked immunosorbent assay techniques.

"Serum albumin level was determined by the Bromocresol green method, while the CD4 lymphocyte count was obtained using the Dynal T4 count method. Body weight was measured in kilograms with light clothes on," H.O. Olawumi and colleagues at the University of Ilorin wrote.

"There were significant positive correlations between pretreatment albumin and both pretreatment CD4 cell count and pretreatment weight, and between post-treatment albumin and both post-treatment weight and post-treatment CD4 cell count up to a count of 700 cells/mcL.

"There were also significant positive correlations between increase in serum albumin and both increase in body weight and duration of treatment," reported investigators.

The authors concluded that in "developing countries where many patients may not be able to afford to pay for CD4 cell counts and viral load tests, which are the traditional markers for HIV disease, serum albumin would be a very useful surrogate test for predicting severity of HIV infection and for clinical monitoring of response to antiretroviral therapy."

Olawumi and colleagues published their study in HIV Medicine (The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients. HIV Med. 2006 Sep;7(6):351-5).

For additional information, contact P.O. Olatunji, University of Ilorin, Teaching Hospital, Dept. of Hematology & Blood Transfusion, Ilorin, Nigeria.

The publisher's contact information for the journal HIV Medicine is: Blackwell Publishing, 9600 Garsington Rd., Oxford OX4 2DQ, Oxon, England.

Keywords: Ilorin, Nigeria, HIV/AIDS, Prognostic Indicator, Serum Albumin, Clinical Monitoring, Resource-Poor Setting.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Olawumi HO, Olatunji PO., “The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients”, HIV Med. 2006 Sep;7(6):351-5.

PubMED Related articles Search

2006-10-02
AW061003

Copyright © 2006 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.